Blake Salisbury currently leads BD activities as the VP of Business Development at Innovent Biologics, a China based innovative biopharmaceutical company.  Blake has 27 years of experience in pharma/biotech, primarily in business development (20 years), but also in sales, marketing, and pricing. While at Innovent, Blake has in-licensed and out-licensed various early stage assets to/from partners in China, he led a global co-development deal to develop and commercialize a bispecific antibody with Hanmi Pharmaceuticals, and in 2018 he in-licensed 3 late stage oncology small molecules from Incyte for the China market. Prior to joining Innovent, Blake spent almost 24 years with Eli Lilly and Company where he closed over 50 transactions of various types, many of which were notable transactions with Chinese companies, starting as early as 2006.  Blake’s last position at Lilly was as a Senior Director of Corporate Business Development – responsible for in-license, out-license, and M&A activities supporting Lilly’s various Business Units.